Anticoagulant activity of original synthetic peptide derivatives.
Original synthetic peptide derivatives exhibit anticoagulant activity in vitro and in vivo. They delayed fibrin clot formation from human blood plasma in tests for the intrinsic coagulation pathway (activated partial thromboplastin time) and final stage of plasma coagulation (thrombin time) and inhibited amidolytic activity of thrombin. We determined the minimum effective dose of the most active compound providing a 2-fold lengthening of blood clotting time (activated partial thromboplastin time test and thrombin time test), which persisted for 2-3 h.
Drozd
N N
NN
Laboratory for Pathology and Pharmacology of Hemostasis, Hematology Research Center, Russian Academy of Medical Sciences. nndrozd@mail.com
Tolstenkov
A S
AS
Makarov
V A
VA
Miphtakhova
N T
NT
Voyushina
T L
TL
Sergeev
M E
ME
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D010455:Peptides / Q000138:chemical synthesis* / Q000235:genetics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013917:Thrombin / Q000378:metabolism
D000925:Anticoagulants; D010455:Peptides; D013917:Thrombin